title: [Correlation between the level of the urinary 11-dehydrothromboxane B2 and the clinical efficacy of aspirin in patients with type 2 diabetes and coronary artery disease].
abstract: OBJECTIVE
  To elucidate the correlation between urinary 11-dehydro-thromboxane B2 (11dhTxB2) and clinical efficacy of aspirin treatment in patients with type 2 diabete and coronary artery disease (CAD).
  
  
  METHODS
  In this prospective cohort study, 169 aged patients with type 2 diabete accompanying CAD in Peking University First Hospital were enrolled. The level of urinary 11dhTxB2 was detected using enzyme-linked immuno-sorbent assay. Low aspirin response or high on aspirin platelet reactivity (HAPR) was defined as urinary 11dhTxB2>1 500 ng/g. All the included patients were divided into two groups based on the results, HAPR group and No-HAPR group.
  
  
  RESULTS
  Baseline urinary 11dhTxB2 of the patients with type 2 diabete accompanying CAD was (3 687±3 052) ng/g, while the urinary 11dhTxB2 was (1 954±859) ng/g in patients after 100 mg/d aspirin treatment (P<0.001). Prevalence of HAPR in patients with type 2 diabete accompanying CAD were 32.5%. Within a mean follow-up time of 12 months, the outcomes occurred more frequently in HAPR group than in No-HAPR group (P<0.05).
  
  
  CONCLUSIONS
  Urinary 11dhTxB2 can be recognized as an effective indicator in evaluating aspirin clinical efficacy of patients with type 2 diabete accompanying CAD.
authors.affiliation: Department of Geriatrics, Peking University First Hospital, Beijing 100034, China.
authors.forename: Teng-fei
authors.initials: TF
authors.lastname: Liu
authors.affiliation: Department of Geriatrics, Peking University First Hospital, Beijing 100034, China.
authors.forename: Jing-wei
authors.initials: JW
authors.lastname: Zhang
authors.affiliation: Department of Geriatrics, Peking University First Hospital, Beijing 100034, China.
authors.forename: Xia-huan
authors.initials: XH
authors.lastname: Chen
authors.affiliation: Department of Geriatrics, Peking University First Hospital, Beijing 100034, China.
authors.forename: Xue-ru
authors.initials: XR
authors.lastname: Feng
authors.affiliation: Department of Geriatrics, Peking University First Hospital, Beijing 100034, China.
authors.forename: Zhong-sheng
authors.initials: ZS
authors.lastname: Bai
authors.affiliation: Department of Geriatrics, Peking University First Hospital, Beijing 100034, China.
authors.forename: Mei-lin
authors.initials: ML
authors.lastname: Liu
mesh_terms: D001241:Aspirin / Q000627:therapeutic use*; D000068476:Beijing; D001792:Blood Platelets / Q000187:drug effects; D003324:Coronary Artery Disease / Q000188:drug therapy*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D011446:Prospective Studies; D013929:Thromboxane B2 / Q000031:analogs & derivatives* / Q000652:urine; D016896:Treatment Outcome
chemical_list: D010975:Platelet Aggregation Inhibitors; D013929:Thromboxane B2; C049235:11-dehydro-thromboxane B2; D001241:Aspirin